In this article NES.N-CH Follow your favorite stocks CREATE FREE ACCOUNTwatch nowThe meteoric rise of weight loss drugs means consumers' nutritional needs are "shifting" which provides new opportunities for food companies, Nestle CEO Mark Schneider told CNBC.
"I think what since has emerged is that nutritional needs don't go away.
So, you know before, during, after GLP-1 therapy — consumers still have nutritional needs, but they may be different from someone who is not on a weight loss regimen."
According to Schneider, consumers who are on weight loss medication simply have different nutritional needs.
Nestle is also planning other "companion offerings" for consumers taking weight loss drugs, both in the U.S., where Vital Pursuit products will launch, and elsewhere, Schneider said.
Persons:
Mark Schneider, Schneider, CNBC's Silvia Amaro, Nestle, they're
Organizations:
Nestle, CNBC, Investors
Locations:
Swiss, U.S